Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 08 Nov 2024 15:18 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Mandatory Notification of Trade by Closely Associated Party of a Primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 08 Nov 2024 15:10 CET |
NYKODE THERAPEUTICS ASA | Disclosure of large shareholding in Nykode Therapeutics ASA | 20103010 Biotechnology | Major shareholding notifications |
| 08 Nov 2024 00:15 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – Webcast Invitation | 20103010 Biotechnology | Non-regulatory press releases |
| 07 Nov 2024 23:25 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to Regain Control of VB10.NEO Program | 20103010 Biotechnology | Inside information |
| 06 Nov 2024 17:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe | 20103010 Biotechnology | Non-regulatory press releases |
| 27 Sep 2024 08:11 CEST |
NYKODE THERAPEUTICS ASA | Major shareholding notification | 20103010 Biotechnology | Major shareholding notifications |
| 21 Aug 2024 16:20 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 21 Aug 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q2 2024 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 21 Aug 2024 06:30 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Strategic Repositioning of VB10.16 to Focus on Locally Advanced Cervical Cancer and Recurrent Metastatic Head and Neck Cancer | 20103010 Biotechnology | Inside information |
| 14 Aug 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines | 20103010 Biotechnology | Non-regulatory press releases |
| 01 Aug 2024 08:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q2 2024 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |
| 01 Jul 2024 20:20 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Grant of share options | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 20 Jun 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting | 20103010 Biotechnology | Non-regulatory press releases |
| 11 Jun 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy | 20103010 Biotechnology | Non-regulatory press releases |
| 24 May 2024 17:15 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Grant of share options | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 16 May 2024 11:46 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Minutes of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 14 May 2024 07:15 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 14 May 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q1 2024 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 07 May 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q1 2024 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |
| 25 Apr 2024 07:30 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Notice of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Apr 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 19 Apr 2024 06:30 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Annual Report 2023 | 20103010 Biotechnology | Annual financial and audit Reports |
| 26 Mar 2024 15:30 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 21 Mar 2024 19:38 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 21 Mar 2024 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 19 Mar 2024 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases | 20103010 Biotechnology | Non-regulatory press releases |
| 13 Mar 2024 14:57 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 08 Mar 2024 16:16 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 08 Mar 2024 13:31 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 04 Mar 2024 13:11 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 29 Feb 2024 16:27 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 28 Feb 2024 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q4 2023 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 22 Feb 2024 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q4 2023 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |
| 19 Dec 2023 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 18 Dec 2023 21:19 CET |
NYKODE THERAPEUTICS ASA | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 14 Dec 2023 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 07 Dec 2023 18:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
| 28 Nov 2023 10:49 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
| 24 Nov 2023 18:20 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – Primary insider transaction | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 15 Nov 2023 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q3 2023 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 10 Nov 2023 17:13 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
| 09 Nov 2023 08:30 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q3 2023 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |
| 07 Nov 2023 08:30 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to Present at Jefferies Healthcare Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 31 Oct 2023 15:30 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 31 Oct 2023 14:41 CET |
NYKODE THERAPEUTICS ASA | Disclosure of shareholding | 20103010 Biotechnology | Major shareholding notifications |
| 31 Oct 2023 09:16 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA – New Share Capital Registered | 20103010 Biotechnology | Total number of voting rights and capital |
| 30 Oct 2023 23:29 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA – Subsequent Offering Cancelled | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 27 Oct 2023 16:15 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 25 Oct 2023 17:22 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of trade by closely associated party of a primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 25 Oct 2023 15:32 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of trade by closely associated party of a primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |